Ipsen SA (IPN) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.125x

Based on the latest financial reports, Ipsen SA (IPN) has a cash flow conversion efficiency ratio of 0.125x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€526.70 Million ≈ $615.77 Million USD) by net assets (€4.23 Billion ≈ $4.95 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Ipsen SA's balance sheet to measure how much of total assets are equity-financed.

Ipsen SA - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how Ipsen SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Ipsen SA to evaluate the quality of earnings relative to operating cash generation.

Ipsen SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ipsen SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Itaúsa - Investimentos Itaú SA
SA:ITSA3
-0.002x
Boston Properties Inc
NYSE:BXP
0.020x
RAKUTEN GROUP SPONS.ADR 1
F:RAKA
0.382x
Chandra Asri Petrochemical Tbk
JK:TPIA
0.058x
Yangzijiang Shipbuilding (Holdings) Ltd
F:B8O
0.034x
REC Limited
NSE:RECLTD
-0.035x
Insurance Australia Group Limited
F:NRM
0.010x
Crane Company
NYSE:CR
-0.063x

Annual Cash Flow Conversion Efficiency for Ipsen SA (2002–2024)

The table below shows the annual cash flow conversion efficiency of Ipsen SA from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Ipsen SA (IPN) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €4.18 Billion
≈ $4.89 Billion
€915.50 Million
≈ $1.07 Billion
0.219x -3.32%
2023-12-31 €3.82 Billion
≈ $4.47 Billion
€865.90 Million
≈ $1.01 Billion
0.226x -22.22%
2022-12-31 €3.34 Billion
≈ $3.90 Billion
€971.40 Million
≈ $1.14 Billion
0.291x -12.34%
2021-12-31 €2.74 Billion
≈ $3.20 Billion
€909.20 Million
≈ $1.06 Billion
0.332x -8.12%
2020-12-31 €2.13 Billion
≈ $2.49 Billion
€771.30 Million
≈ $901.73 Million
0.361x +0.94%
2019-12-31 €1.75 Billion
≈ $2.05 Billion
€627.70 Million
≈ $733.85 Million
0.358x +15.62%
2018-12-31 €1.84 Billion
≈ $2.16 Billion
€570.90 Million
≈ $667.44 Million
0.310x +12.48%
2017-12-31 €1.54 Billion
≈ $1.80 Billion
€422.90 Million
≈ $494.41 Million
0.275x +18.02%
2016-12-31 €1.36 Billion
≈ $1.59 Billion
€317.80 Million
≈ $371.54 Million
0.233x +27.88%
2015-12-31 €1.23 Billion
≈ $1.43 Billion
€223.60 Million
≈ $261.41 Million
0.182x -20.74%
2014-12-31 €1.07 Billion
≈ $1.25 Billion
€245.80 Million
≈ $287.37 Million
0.230x +19.15%
2013-12-31 €973.70 Million
≈ $1.14 Billion
€188.10 Million
≈ $219.91 Million
0.193x +24.07%
2012-12-31 €926.25 Million
≈ $1.08 Billion
€144.22 Million
≈ $168.61 Million
0.156x -9.89%
2011-12-31 €1.02 Billion
≈ $1.19 Billion
€175.45 Million
≈ $205.11 Million
0.173x -26.56%
2010-12-31 €1.08 Billion
≈ $1.26 Billion
€253.91 Million
≈ $296.85 Million
0.235x -10.11%
2009-12-31 €984.35 Million
≈ $1.15 Billion
€257.62 Million
≈ $301.19 Million
0.262x +11.75%
2008-12-31 €868.49 Million
≈ $1.02 Billion
€203.41 Million
≈ $237.81 Million
0.234x +6.63%
2007-12-31 €801.11 Million
≈ $936.58 Million
€175.97 Million
≈ $205.73 Million
0.220x -51.20%
2006-12-31 €727.90 Million
≈ $851.00 Million
€327.63 Million
≈ $383.04 Million
0.450x +86.93%
2005-12-31 €621.10 Million
≈ $726.13 Million
€149.55 Million
≈ $174.84 Million
0.241x -44.79%
2004-12-31 €197.73 Million
≈ $231.17 Million
€86.23 Million
≈ $100.82 Million
0.436x -10.31%
2003-12-31 €311.65 Million
≈ $364.36 Million
€151.54 Million
≈ $177.17 Million
0.486x +18.78%
2002-12-31 €227.95 Million
≈ $266.50 Million
€93.32 Million
≈ $109.10 Million
0.409x --

About Ipsen SA

PA:IPN France Drug Manufacturers - Specialty & Generic
Market Cap
$14.75 Billion
€12.61 Billion EUR
Market Cap Rank
#2138 Global
#43 in France
Share Price
€153.10
Change (1 day)
-8.43%
52-Week Range
€105.30 - €172.90
All Time High
€172.90
About

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more